Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/KRT6A_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/KRT6A_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/KRT6A_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/KRT6A_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004206010 | Cervix | CC | wound healing | 109/2311 | 422/18723 | 1.84e-14 | 1.57e-11 | 109 |
GO:005212610 | Cervix | CC | movement in host environment | 52/2311 | 175/18723 | 7.03e-10 | 8.76e-08 | 52 |
GO:004440910 | Cervix | CC | entry into host | 47/2311 | 151/18723 | 8.45e-10 | 1.03e-07 | 47 |
GO:005170110 | Cervix | CC | biological process involved in interaction with host | 57/2311 | 203/18723 | 1.18e-09 | 1.41e-07 | 57 |
GO:004440310 | Cervix | CC | biological process involved in symbiotic interaction | 71/2311 | 290/18723 | 7.94e-09 | 6.98e-07 | 71 |
GO:00523728 | Cervix | CC | modulation by symbiont of entry into host | 15/2311 | 49/18723 | 5.81e-04 | 5.52e-03 | 15 |
GO:004390310 | Cervix | CC | regulation of biological process involved in symbiotic interaction | 19/2311 | 72/18723 | 9.11e-04 | 7.81e-03 | 19 |
GO:00313423 | Cervix | CC | negative regulation of cell killing | 10/2311 | 28/18723 | 1.28e-03 | 1.02e-02 | 10 |
GO:00197308 | Cervix | CC | antimicrobial humoral response | 27/2311 | 122/18723 | 1.70e-03 | 1.29e-02 | 27 |
GO:00019067 | Cervix | CC | cell killing | 37/2311 | 188/18723 | 2.61e-03 | 1.80e-02 | 37 |
GO:00618447 | Cervix | CC | antimicrobial humoral immune response mediated by antimicrobial peptide | 18/2311 | 79/18723 | 6.82e-03 | 3.74e-02 | 18 |
GO:00069597 | Cervix | CC | humoral immune response | 54/2311 | 317/18723 | 8.57e-03 | 4.42e-02 | 54 |
GO:000695912 | Cervix | HSIL_HPV | humoral immune response | 39/737 | 317/18723 | 2.88e-10 | 7.02e-08 | 39 |
GO:004440915 | Cervix | HSIL_HPV | entry into host | 24/737 | 151/18723 | 5.42e-09 | 7.61e-07 | 24 |
GO:005212615 | Cervix | HSIL_HPV | movement in host environment | 25/737 | 175/18723 | 2.41e-08 | 2.18e-06 | 25 |
GO:004440315 | Cervix | HSIL_HPV | biological process involved in symbiotic interaction | 33/737 | 290/18723 | 4.67e-08 | 3.59e-06 | 33 |
GO:004206015 | Cervix | HSIL_HPV | wound healing | 40/737 | 422/18723 | 2.80e-07 | 1.61e-05 | 40 |
GO:005170115 | Cervix | HSIL_HPV | biological process involved in interaction with host | 25/737 | 203/18723 | 4.50e-07 | 2.36e-05 | 25 |
GO:001973012 | Cervix | HSIL_HPV | antimicrobial humoral response | 18/737 | 122/18723 | 1.35e-06 | 6.21e-05 | 18 |
GO:000190611 | Cervix | HSIL_HPV | cell killing | 23/737 | 188/18723 | 1.45e-06 | 6.47e-05 | 23 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
KRT6A | SNV | Missense_Mutation | rs62635293 | c.491G>A | p.Arg164His | p.R164H | P02538 | protein_coding | deleterious(0.01) | possibly_damaging(0.88) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
KRT6A | SNV | Missense_Mutation | rs758984854 | c.244G>A | p.Gly82Ser | p.G82S | P02538 | protein_coding | tolerated(0.15) | benign(0.005) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
KRT6A | SNV | Missense_Mutation | rs764320645 | c.1510N>A | p.Gly504Ser | p.G504S | P02538 | protein_coding | tolerated(0.3) | benign(0.003) | TCGA-A5-A0R9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
KRT6A | SNV | Missense_Mutation | novel | c.1508N>A | p.Val503Asp | p.V503D | P02538 | protein_coding | tolerated(0.12) | benign(0.01) | TCGA-A5-A0R9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
KRT6A | SNV | Missense_Mutation | novel | c.1016N>T | p.Ala339Val | p.A339V | P02538 | protein_coding | deleterious(0.01) | probably_damaging(0.948) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
KRT6A | SNV | Missense_Mutation | novel | c.750N>T | p.Lys250Asn | p.K250N | P02538 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
KRT6A | SNV | Missense_Mutation | novel | c.1310N>T | p.Ala437Val | p.A437V | P02538 | protein_coding | deleterious(0) | probably_damaging(0.968) | TCGA-AJ-A3BH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
KRT6A | SNV | Missense_Mutation | novel | c.430N>A | p.Leu144Ile | p.L144I | P02538 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
KRT6A | SNV | Missense_Mutation | rs201401681 | c.1223N>T | p.Ala408Val | p.A408V | P02538 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
KRT6A | SNV | Missense_Mutation | rs533157590 | c.44N>A | p.Arg15His | p.R15H | P02538 | protein_coding | tolerated(0.28) | benign(0) | TCGA-AX-A2H7-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |